Company:  SUNESIS PHARMACEUTICALS I ... (SNSS)
Form Type:  10-Q
Filing Date:  5/15/2012 
CIK:  0001061027 
Address:  395 OYSTER POINT BOULEVARD
SUITE 400
 
City, State, Zip:  SOUTH SAN FRANCISCO, California 94080 
Telephone:  650-266-3500 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$5.29  
Change: 
-0.07 (-1.31%)  
Trade Time: 
Apr 24  
Market Cap: 
$317.90M
Description of Business
We are a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. Our efforts are currently focused primarily on the development of vosaroxin for the treatment of acute myeloid leukemia, or AML. Vosaroxin is a first-in-class anti-cancer quinolone derivative, or AQD�a class of compounds that has not been used previously for the treatment of cancer. In earlier studies, vosaroxin has been shown to mediate anti-tumor activity by targeting mammalian topoisomerase II, an enzyme critical for cell replication. We have built a highly experienced cancer drug development organization committed to advancing vosaroxin in multiple indications to improve the lives of people with cancer.
Register for EDGAR Pro and access this filing in:     
  FORM 10-Q
    PART I - FINANCIAL INFORMATION
      Item 1. Financial Statements
        BALANCE SHEET
        CASH FLOW
        NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
      Item 2. Management's Discussion and Analysis of Financial ...
      Item 3. Quantitative and Qualitative Disclosures About ...
      Item 4. Controls and Procedures
    PART II. OTHER INFORMATION
      Item 1. Legal Proceedings
      Item 1A. Risk Factors
      Item 2. Unregistered Sales of Equity Securities and Use of ...
      Item 3. Defaults Upon Senior Securities
      Item 4. Mine Safety Disclosures
      Item 5. Other Information
      Item 6. Exhibits
    SIGNATURE
    EXHIBIT INDEX
  EXHIBIT 10.6
  EXHIBIT 10.7
  EXHIBIT 10.8
  EXHIBIT 31.1
    Certification of Chief Executive Officer
  EXHIBIT 31.2
    Certification of Chief Financial Officer
  EXHIBIT 32.1
    Certification
BROKERAGE PARTNERS